DiscoverTreating TogetherS6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
S6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

S6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Update: 2025-02-06
Share

Description

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan for the treatment of patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

S6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Targeted Oncology